急性冠脉综合征合并肾功能不全患者远期预后研究-东南大学学报医学版

急性冠脉综合征合并肾功能不全患者远期预后研究

单位：1. 东南大学附属中大医院心血管内科, 江苏南京 210009;
2. 上海市第六人民医院心血管内科, 上海 200120

分类号：R543.3;R692.5

出版年·卷·期（页码）：2014·33·第三期（267-271）

摘要：

目的：探讨急性冠脉综合征患者的肾功能对远期预后的影响。方法：选取2010年1月至2011年12月在东南大学附属中大医院心脏科住院治疗的390例急性冠脉综合征患者，分为急性ST段抬高心肌梗死（n=171）和不稳定心绞痛/非ST段抬高心肌梗死（n=219）两组，每组根据肾小球滤过率（estimated glomerular filtration rate，eGFR）分为eGFR 正常组[eGFR≥90 ml·min^-1·（1.73 m）^-2]和eGFR降低组[eGFR<90 ml·min^-1·（1.73 m）^-2]两个亚组。分析各亚组病变血管情况、临床生化指标、合并症以及治疗情况，并对所有患者进行12~36个月随访，观察各组远期严重心血管不良事件的发生情况。结果：急性ST段抬高心肌梗死患者中，eGFR正常患者108例，34例（31.5%）出现严重心血管不良事件；eGFR降低者63例，26例（41.3%）出现严重心血管不良事件，两亚组严重心血管不良事件发生率差异无统计学意义（风险比1.426，95%置信区间0.855~2.378，P=0.174）。12~36个月随访中两亚组严重心血管不良事件发生风险差异无统计学意义（P=0.065），但eGFR降低组患者的严重心血管不良事件发生率呈现明显的上升趋势。不稳定心绞痛/非ST段抬高心肌梗死患者中，eGFR正常者140例，41例（38.0%）发生严重心血管不良事件；eGFR降低者79例，18例（28.6%）出现严重心血管不良事件，两亚组严重心血管不良事件发生率差异无统计学意义（风险比0.836，95%置信区间0.480~1.455，P=0.526）。12~36个月随访两亚组严重心血管不良事件发生风险差异无统计学意义（P=0.522）。结论：肾功能不全的急性心肌梗死患者远期发生严重心血管不良事件的风险与肾功能正常患者相比有上升趋势，但尚无统计学意义。

Objective:To determine the long-term outcomes in acute coronary syndrome(ACS) patients with or without chronic kidney disease(CKD). Methods:390 ACS patients who were treated in Zhongda Hospital from Jan, 2010 to Dec, 2011 were enrolled in the study. These patients were divided into two groups:ST elevated myocardial infarction(STEMI) group(n=171) and non ST elevated myocardial infarction(non-STEMI) group(n=219). Each group was divided into two subgroups according to the estimated glomerular filtration rate(eGFR):normal eGFR subgroup[eGFR≥90 ml·min^-1·(1.73 m) ^-2] and low eGFR subgroup[eGFR<90 ml·min^-1·(1.73 m) ^-2]. Basic clinical characters were analyzed and major adverse cardiovascular events(MACEs) were observed during 12~36 months follow-up. Results:In STEMI group, 108 patients had normal renal function, MACEs happened in 34 patients(31.5%). 63 patients had renal dysfunction, MACEs happened in 26 patients(41.3%). The incidence of MACEs had no significant difference between two subgroups(Hazard ratio 1.426, 95% confidence interval 0.855-2.378, P=0.174). The cumulative hazard of MACEs between two subgroups had no significant difference(P=0.065). However, increasing trend of MACEs incidence was observed in low eGFR subgroup. In non-STEMI group, 140 patients had normal renal function, MACEs happened in 41 patients(38.0%). 79 patients had renal dysfunction, MACEs happened in 18 patients(28.6%). The incidence of MACEs had no significant difference between two subgroups(Hazard ratio 0.836, 95% cofidence interval 0.480-1.455, P=0.526). The cumulative hazard of MACEs between two subgroups had no significant difference(P=0.522). Conclusion:STEMI patients with renal dysfunction have increased risk of MACEs in long term follow-up compared with normal renal function, although statistical significant was not detected.

参考文献：

[1] HE J,GU D,WU X,et al.Major causes of death among men and women in China[J].N Engl J Med,2005,353(11):1124-1134.
[2] ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
[3] GRAND'MAISON A,CHAREST A F,GEERTS W H.Antic0agulant use in patients with chronic renal impairment[J].Am J Cardiovasc Drugs,2005(5):291-305.
[4] EZEKOWITZ J,MCALISTER F A,HUMPHRIES K H,et al.The association among renal insufficiency,pharmacotherapy,and outcomes in 6,427 patients with heart failureand coronary artery disease[J].J Am Coll Cardiol,2004,44(8):1587-1592.
[5] MEHRAN R,NIKOLSKY E,LANSKY A J,et al.Impact of chronic kidney disease on early(30-day) and late(1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies:an ACUITY(Acute Catheterization and Urgent Intervention Triage strategy) substudy[J].JACC Cardiovasc Interv,2009,2(8):748-757.
[6] SAGRIPANTI A,COZZA V,BAICCHI U,et al.Increased thrombin generation in patients with chronic renal failure[J].Int J Clin Lab Res,1997,27(1):72-75.
[7] POULIKAKOS D,BANERJEE D,MALIK M.Risk of sudden cardiac death in chronic kidney disease[J].J Cardiovasc Electrophysiol,2013.
[8] KOUSHOLT B S.Natriuretic peptides as therapy in cardiac ischaemia/reperfusion[J].Dan Med J,2012,59(6):B4469.
[9] STEG P G,JAMES S K,ATAR D,et al.Third universal definition of myocardial infarction[J].Eur Heart J,2012,80(12):777-786.
[10] HOCHHOLZER W,WIVIOTT S D,ANTMAN E M,et al.Predictors of bleeding and time dependence of association of bleeding with mortality:insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38(TRITON-TIMI 38) [J].Circulation,2011,123(23):2681-2689.
[11] BLICHER T M,HOMMEL K,OLESEN J B,et al.Less use of standard guideline-based treatment of myocardial infarction in patients with chronic kidney disease:a Danish nation-wide cohort study[J].Eur Heart J,2013,34(37):2916-2923.
[12] ARBEL Y,HALKIN A,FINKELSTEIN A,et al.Impact of estimated glomerular filtration rate on vascular disease extent and adverse cardiovascular events inpatients without chronic kidney disease[J].Can J Cardiol,2013,29(11):1374-1381.
[13] KITAI Y,OZASA N,MORIMOTO T,et al.Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention[J].Int J Cardiol,2013,168(6):5221-5228.
[14] WANITSCHEK M,PFISTERER M,HVELPLUND A,et al.Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease[J].Int J Cardiol,2013,168(3):2381-2388.
[15] DEO S V,SHAH I K,DUNLAY S M,et al.Myocardial revascularization in renal dysfunction:a systematic review and meta-analysis[J].Heart Lung Circ,2013,22(10):827-835.
[16] HOLZMANN M J,AHLBCK E,JEPPSSON A,et al.Renal dysfunction and long-term risk of ischemic and hemorrhagic stroke following coronary artery by pass grafting[J].Int J Cardiol,2013,168(2):1137-1142.
[17] LI Y H,LIN G M,LIN C L,et al.Relation of estimated glomerular filtration rate and body mass index to mortality in non-dialysis patients with coronary artery disease:a report from the ET-CHD registry,1997-2003[J].J Cardiol,2013,62(3):144-150.
[18] BALTANS A,MIGUEL-CARRASCO J L,SAN-JOS G,et al.A synthetic peptide from transforming growth factor-β1 type Ⅲ receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats[J].Antioxid Redox Signal,2013,19(14):1607-1618.
[19] 智宏,任利群,马根山,等.冠心病合并代谢综合征者炎症因子水平与冠脉病变程度的研究[J].东南大学学报:医学版,2009,28(1):10-12.
[20] ZHANG S,ZHAO Y,XU M,et al.FoxO3a modulates hypoxia stress induced oxidative stress and apoptosis in cardiac microvascular endothelial cells[J].PLoS One,2013,8(11):e80342.
[21] 张静梅,黄爱军,凌立君.曲美他嗪治疗冠心病患者内皮细胞损伤的临床研究[J].东南大学学报:医学版,2010,29(1):93-95.
[22] MATSUZAWA Y,SUGIYAMA S,SUMIDA H,et al.Peripheral endothelial function and cardiovascular events in high-risk patients[J].J Am Heart Assoc,2013,2(6):e000426.
[23] IYER H,ABRAHAM G,REDDY Y N,et al.Risk factors of chronic kidney disease influencing cardiac calcification[J].Saudi J Kidney Dis Transpl,2013,24(6):1189-1194.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录